Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
PRPH 
ProPhase Labs Inc (PRPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: PRPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.8
1 Year Target Price $13.8
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.1% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.83M USD | Price to earnings Ratio - | 1Y Target Price 13.8 |
Price to earnings Ratio - | 1Y Target Price 13.8 | ||
Volume (30-day avg) 1 | Beta -0.55 | 52 Weeks Range 0.17 - 7.80 | Updated Date 01/9/2026 |
52 Weeks Range 0.17 - 7.80 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -539.52% |
Management Effectiveness
Return on Assets (TTM) -23.5% | Return on Equity (TTM) -220.34% |
Valuation
Trailing PE - | Forward PE 10.09 | Enterprise Value 8137101 | Price to Sales(TTM) 0.16 |
Enterprise Value 8137101 | Price to Sales(TTM) 0.16 | ||
Enterprise Value to Revenue 1.61 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 4187902 | Shares Floating 4284582 |
Shares Outstanding 4187902 | Shares Floating 4284582 | ||
Percent Insiders 5.51 | Percent Institutions 5.03 |
Upturn AI SWOT
ProPhase Labs Inc
Company Overview
History and Background
ProPhase Labs Inc. (NASDAQ: PRPH) has a history that includes a significant shift in its business model. Originally known as PAO Group, Inc., the company has transitioned from a diverse portfolio including metal fabrication, machinery, and telecommunications to a focus on the health and wellness sector, particularly through its wholly-owned subsidiary, ProPhase Pharma, Inc. This strategic pivot aimed to capitalize on the growing demand for dietary supplements and over-the-counter (OTC) health products. Key milestones include the rebranding and focus on health products, and efforts to develop and market innovative health solutions. The evolution reflects a response to market opportunities and a desire for increased specialization.
Core Business Areas
- Health and Wellness Products: ProPhase Labs Inc. operates primarily in the health and wellness sector, focusing on the development, marketing, and distribution of dietary supplements and other health-related products. This segment encompasses a range of products designed to support various aspects of health and well-being.
- Research and Development: The company is also involved in research and development activities, particularly in identifying and potentially commercializing new health products or formulations. This includes exploring opportunities within the pharmaceutical and nutraceutical spaces.
Leadership and Structure
ProPhase Labs Inc. is led by a management team responsible for its strategic direction and operational execution. The organizational structure supports its focus on the health and wellness market, with dedicated teams for product development, marketing, sales, and regulatory compliance. Specific details on the leadership team can be found in their official filings with the SEC.
Top Products and Market Share
Key Offerings
- Competitors: Numerous pharmaceutical and diagnostic companies, including Abbott Laboratories, QuidelOrtho, Becton Dickinson, and many others.
- Description: ProPhase Labs has been involved in the distribution of rapid COVID-19 antigen tests. This was a significant revenue driver during the peak of the pandemic.
- Market Share Data: Precise market share data for this specific product line is difficult to ascertain as it was a rapidly evolving and highly competitive market. The company was one of many suppliers.
- Product Name 1: COVID-19 Testing Kits (e.g., antigen tests)
- Competitors: GNC, Nature's Bounty, NOW Foods, Thorne, Garden of Life, and a vast number of smaller online and brick-and-mortar retailers.
- Description: The company offers a range of dietary supplements targeting various health needs, including immune support, energy, and general wellness. These are marketed under various brands.
- Market Share Data: Market share for individual supplement products is highly fragmented. ProPhase Labs operates within a competitive landscape with many niche and established players.
- Product Name 2: Dietary Supplements
Market Dynamics
Industry Overview
ProPhase Labs operates within the broad health and wellness industry, which is characterized by increasing consumer interest in preventative health, natural products, and personalized wellness solutions. The dietary supplement market is robust and growing, driven by factors such as an aging population, rising health consciousness, and the desire for convenient health solutions. The diagnostic testing market, particularly for infectious diseases, is dynamic and responsive to public health events.
Positioning
ProPhase Labs positions itself as a provider of innovative and accessible health products. Its competitive advantages lie in its agility to respond to market demands, its focus on specific health niches, and its distribution capabilities. The company aims to leverage its R&D to introduce differentiated products. However, it faces intense competition from both large, established players and numerous smaller, agile companies.
Total Addressable Market (TAM)
The total addressable market for dietary supplements is estimated to be in the tens of billions of dollars globally, with significant growth projected. The market for diagnostic testing, especially for infectious diseases, can also be substantial, fluctuating with public health needs. ProPhase Labs' positioning is as a participant in these large markets, aiming to capture a niche share through its product offerings and strategic initiatives.
Upturn SWOT Analysis
Strengths
- Agility in responding to market trends, as demonstrated by its pivot to health products and COVID-19 testing.
- Focus on the growing health and wellness sector.
- Potential for developing niche, innovative health products.
- Established distribution channels for its products.
Weaknesses
- Brand recognition may be less established compared to larger competitors in the supplement market.
- Reliance on specific product categories (e.g., past reliance on COVID-19 testing) can create revenue volatility.
- Limited financial resources compared to major players.
- Need to continually invest in R&D to stay competitive.
Opportunities
- Increasing consumer demand for natural and science-backed health supplements.
- Expansion into new health product categories and formulations.
- Partnerships with healthcare providers or retailers for wider distribution.
- Leveraging online platforms for direct-to-consumer sales and brand building.
- Potential for international market expansion.
Threats
- Intense competition from established and emerging players in the health and wellness market.
- Regulatory changes or challenges related to dietary supplements and health claims.
- Economic downturns affecting consumer spending on non-essential health products.
- Supply chain disruptions for raw materials or finished goods.
- Emergence of new health crises that shift market focus.
Competitors and Market Share
Key Competitors
- GNC Holdings LLC (Private)
- Nature's Bounty Co. (Private)
- Bausch Health Companies Inc. (BHC)
- Amneal Pharmaceuticals LLC (AMRX)
Competitive Landscape
ProPhase Labs operates in a highly competitive landscape. Its advantages include its focused approach to health and wellness and its agility. However, it faces disadvantages in terms of scale, brand recognition, and marketing budgets compared to larger, well-established competitors. The company must continuously differentiate itself through product quality, innovation, and effective market penetration strategies.
Growth Trajectory and Initiatives
Historical Growth: ProPhase Labs Inc.'s historical growth has been marked by significant shifts in its business focus. Periods of strong revenue growth have been observed when the company has successfully capitalized on specific market opportunities, such as the demand for COVID-19 testing. However, growth has also been inconsistent due to the evolving nature of its product lines and market dynamics.
Future Projections: Future projections for ProPhase Labs Inc. would depend on its ability to consistently innovate and execute within the health and wellness sector. Analyst estimates, if available, would provide insights into expected revenue growth, profitability, and EPS. Key drivers for future growth would include the success of its dietary supplement lines, potential new product introductions, and strategic partnerships.
Recent Initiatives: Recent initiatives likely focus on expanding its portfolio of dietary supplements, strengthening its marketing and distribution channels, and potentially exploring new product development in emerging health niches. The company may also be focused on optimizing its operations for greater efficiency and profitability.
Summary
ProPhase Labs Inc. has demonstrated adaptability by shifting its focus to the growing health and wellness market. Its strengths lie in its agility and potential for niche product innovation. However, the company faces significant challenges from intense competition, potential revenue volatility, and the need for substantial investment in R&D and marketing. Continued success will depend on its ability to consistently launch effective products, build strong brands, and navigate a dynamic regulatory and economic environment. Careful monitoring of its financial health and strategic execution is essential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial News Websites (e.g., Yahoo Finance, Bloomberg)
- Industry Market Research Reports (general industry data)
- Company Investor Relations Materials (if available)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market conditions can change rapidly. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProPhase Labs Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 1997-01-16 | Chairman & CEO Mr. Ted William Karkus | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 96 | Website https://www.prophaselabs.com |
Full time employees 96 | Website https://www.prophaselabs.com | ||
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.